Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a Phase I open-label dose escalation study

Journal of the American College of Cardiology

Volumn 36, Issue 7, 2000, Pages 2132-2139

  Laham, Roger J ^a   Chronos, Nicholas A ^b   Pike, Marilyn ^c   Leimbach, Mark E ^d   Udelson, James E ^e   Pearlman, Justin D ^a   Pettigrew, Roderic I ^d   Whitehouse, M J ^c   Yoshizawa, Carl ^c   Simons, Michael ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Atlanta Cardiology Group   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE TOLERANCE; FEMALE; HEART INFARCTION; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

AGED; EXERCISE TEST; FEASIBILITY STUDIES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFUSIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 0033667440     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00988-8     Document Type: Article

References (52)

1. The effect of complete and incomplete revascularization on exercise variables in patients undergoing coronary angioplasty
2. Strategy of complete revascularization in patients with multivessel coronary artery disease (a report from the 1985-1986 NHLBI PTCA Registry)
3. Angiogenic therapy of the human heart
4. Therapeutic angiogenesis: A new frontier for vascular therapy
5. Therapeutic angiogenesis in myocardial ischemia
6. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
7. Molecular mechanisms of collateral vessel growth
8. Protamine inhibits coronary collateral development in a canine model of repetitive coronary occlusion
9. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia
10. Fibroblast growth factors: At the heart of angiogenesis
11. Hypotensive activity of fibroblast growth factor
12. Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation
13. Isolation, characterization, and localization of heparin-binding growth factors in the heart
14. Generation and localisation of monoclonal antibodies against fibroblast growth factors in ischaemic collateralised porcine myocardium
15. Basic fibroblast growth factor is cardioprotective in ischemia- reperfusion injury
16. Arterial gene therapy
17. Heparin structure and interactions with basic fibroblast growth factor
18. Heparan sulfate proteoglycans of the cardiovascular system
19. Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: A mechanism for cooperactivity
20. The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction
21. Regulation by heparan sulfate in fibroblast growth factor signaling
22. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor
23. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium
24. Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model
25. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model
26. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart
27. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts
28. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: A comparison of angiographic, echocardiographic and coronary flow parameters
29. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial
30. Comparison of three quality of life instruments in stable angina pectoris: Seattle Angina Questionnaire, Short Form Health Survey (SF-36), and Quality of Life Index-Cardiac Version III
31. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis
32. Contrast-enhanced echo-planar MR imaging of myocardial perfusion: Preliminary study in humans
33. Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: Insight into ischemia-induced reduction in endothelium-dependent vasodilatation
34. Double blind placebo controlled trial of recombinant human vascular endothelial growth factor - The VIVA trial
35. Preclinical and clinical studies with recombinant human basic fibroblast growth factor
36. Angiogenic growth factors and endostatin in non-Hodgkln's lymphoma
37. Vascular response to basic fibroblast growth factor when infused onto the normal adventitia or into the injured media of the rat carotid artery
38. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries
39. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo
40. Angiogenic processes in the pathogenesis of human coronary atherosclerosis
41. Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: In vivo correlation of lesional microvessel density and constrictive vascular remodeling
42. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque
43. Echo planar MRI of the heart on a standard system: Validation of measurements of left ventricular function and mass
44. Automatic assessment of cardiac function from short-axis MRI: Procedure and clinical evaluation
45. Assessment of regional and global left ventricular function by reinjection T1-201 and rest Tc-99m sestamibi ECG-gated SPECT: Comparison with three-dimensional magnetic resonance imaging
46. Assessing myocardial perfusion in coronary artery disease with magnetic resonance first-pass imaging
47. Magnetic resonance imaging evaluation of myocardial perfusion
48. VEGF administration in chronic myocardial ischemia in pigs
49. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a Phase I randomized, double-blind, placebo-controlled trial
50. Intracoronary and intravenous administration of basic fibroblast growth factor: Myocardial and tissue distribution
51. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium
52. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb